Reduction of HIV-1 load in semen during follow-up study of RV144 vaccine trial boosts interest for novel correlates of immune protection in genital mucosa

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1189-1192

  Spetz, Anna Lena ^a,b   Chiodi, Francesca ^b,c  

^a Department of Medicine Huddinge   (Sweden)

^b Centre for HIV Research   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; MUCIN 6; PLACEBO; WART VIRUS VACCINE;

CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; DRUG EFFICACY; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNITY; INFECTION RISK; INFERTILITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEMINAL PLASMA; VACCINATION; VAGINITIS; VIRUS LOAD;

AIDS VACCINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL VACCINES;

EID: 84875633528     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis477     Document Type: Note

References (33)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
2. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
3. Stoiber H. Complement. Fc receptors and antibodies: a Trojan horse in HIV infection? Curr Opin HIV AIDS 2009; 4:394-99.
4. Rerks-Ngarm et al. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 2013; 207:1195-205.
5. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-9.
6. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
7. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82:7932-41.
8. Doria-Rose NA, Klein RM, Manion MM, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83:188-99.
9. Moir S, Malaspina A, Fauci AS. Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol 2011; 18:1317-21.
10. Mudd PA, Watkins DI. Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses. Curr Opin HIV AIDS 2011; 6:197-201.
11. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5:204-10.
12. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-6.
13. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10.
14. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001; 75:7470-80.
15. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-7.
16. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-30.
17. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-4.
18. Willey R, Nason MC, Nishimura Y, Follmann DAMartin MA. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res Hum Retroviruses 2010; 26:89-98.
19. Watkins JD, Siddappa NB, Lakhashe SK, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011; 6: e18207.
20. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-70.
21. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37.
22. Kemp TJ, Garcia-Pineres A, Falk RT, et al. Evaluation of systemic and mucosal anti- HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16.
23. Jespers V, Francis SC, van de Wijgert J, Crucitti T. Methodological issues in sampling the local immune system of the female genital tract in the context of HIV prevention trials. Am J Reprod Immunol 2011; 65:368-76.
24. Jespers V, Harandi AM, Hinkula J, et al. Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines 2010; 9:381-94.
25. Donadoni C, Bisighini C, Scotti L, et al. Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts. PLoS One 2010; 5:e9920.
26. Olivier AJ, Liebenberg LJ, Coetzee D, Williamson AL, Passmore JA, Burgers WA. Isolation and characterization of T cells from semen. J Immunol Methods 2012; 375: 223-31.
27. Gianella S, Strain MC, Rought SE, et al. Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol 2012; 86:1307-15.
28. Ochsendorf FR, Ozdemir K, Rabenau H, et al. Chlamydia trachomatis and male infertility: chlamydia-IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response. J Eur Acad Dermatol Venereol 1999; 12: 143-52.
29. Eggert-Kruse W, Weltin M, Strowitzki T. Are chlamydial lipopolysaccharide-directed antibodies in seminal plasma or serum clinically significant during investigation of male infertility? Urology 2011; 77:1101-6.
30. Kaiser TJ, Christopher-Hennings J, Nelson EA. Measurement of immunoglobulin G, A and M concentrations in boar seminal plasma. Theriogenology 2000; 54:1171-84.
31. Balandya E, Sheth S, Sanders K, Wieland- Alter W, Lahey T. Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J Immunol 2010; 185:7596-604.
32. Stax MJ, van Montfort T, Sprenger RR, et al. Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4+ T-lymphocytes. Virology 2009; 391:203-11.
33. Kim KA, Yolamanova M, Zirafi O, et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010; 7:55.